Aspergillus fumigatus clinical isolates carrying CYP51A TR34/L98H/S297T/F495I mutation detected after 4 years retrospective azole resistance screening test in Brazil.

Aspergillus fumigatus clinical isolates carrying CYP51A TR34/L98H/S297T/F495I mutation detected after 4 years retrospective azole resistance screening test in Brazil. Antimicrob Agents Chemother. 2019 Dec 23;: Authors: Pontes L, Beraquet CAG, Arai T, Pigolli GL, Lyra L, Watanabe A, Moretti ML, Schreiber AZ Abstract Azole antifungals resistance in Aspergillus fumigatus is a worldwide concern. As in most public hospitals in Brazil, antifungal susceptibility tests are not routinely performed for filamentous fungi at our Institution. A 4 years retrospective azole antifungal resistance screening revealed the two azole-resistant A. fumigatus clinical isolates carrying CYP51A TR34/L98H/S297T/F495I mutation resistance mechanism obtained from two unrelated patients. Broth microdilution antifungal susceptibility showed high MICs for Itraconazole, Posaconazole, and Miconazole. STR typing analysis presented high similarity between these two isolates and clinical isolates with the same mutation reported from the Netherlands, Denmark, China, and Taiwan environmental isolates. Our findings might indicate that active searching for resistant A. fumigatus is necessary. It also represents a concern, considering that our Hospital provides tertiary care assistance to immunocompromised patients, that may be exposed to environmental resistant isolates; patients who receive prophylactic antifungal therapy or treatment for invasive fungal infections for year...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research